Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
HAE · NYSE · United States · Surgical & Medical Instruments & Apparatus
In shortHAEMONETICS CORP is profitable, generates cash and carries moderate debt, with revenue stable (−2.0% last year).
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 11.7% | 56/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 7.3% | 49/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 12.0% | 60/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 5.9% | 39/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.95× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 1.54× | 26/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | 3.65× | 10/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 8.12× | 63/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 2.85 | 45/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 19.5% | 98/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 2.68× | 100/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 5 of 5 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 8.0% | 81/100 |
| Operating margin volatility | 2.9% | 82/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 4.5% | 42/100 |
|---|---|---|
| EPS growth, 3-year average | -2.9% | 10/100 |
Weight in the score: 10%
Fiscal year 2026 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 993 | 1,169 | 1,309 | 1,361 | 1,334 |
| Cost of revenue | 488 | 554 | 618 | 612 | 546 |
| Gross profit | 506 | 615 | 692 | 749 | 788 |
| Research & development | 47 | 50 | 54 | 63 | 60 |
| Selling, general & admin | 340 | 377 | 430 | 437 | 442 |
| Operating income | 81 | 156 | 165 | 222 | 157 |
| Interest expense | 5.8 | 13 | 20 | 36 | 19 |
| Pre-tax income | 64 | 141 | 152 | 212 | 128 |
| Income tax | 20 | 26 | 34 | 44 | 31 |
| Net income | 43 | 115 | 118 | 168 | 97 |
| Diluted EPS | $0.84 | $2.24 | $2.29 | $3.31 | $2.05 |
| Diluted shares (millions) | 51 | 51 | 51 | 51 | 47 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
2.85 Safe zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
7/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 27, 2026 · Data updated Aug 6, 2026